An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

Trial Profile

An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs CCX 872 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 22 Jan 2018 According to a ChemoCentryx media release, 18 months results from the study will be presented at the ASCO-SITC Clinical Immuno-Oncology Symposium 2018.
    • 22 Jan 2018 Results published in a ChemoCentryx Media Release
    • 15 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top